An interventional study of recombinant human B-type natriuretic peptide in STEMI, sponsored by Henan Institute of Cardiovascular Epidemiology. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-10.
Sponsored by Henan Institute of Cardiovascular Epidemiology · Not applicable, Interventional, and Treatment
The target population of this interventional study was STEMI patients. Primary discussion: Early rhBNP reduces microcirculation obstruction in STEMI patients undergoing primary PCI
Direct percutaneous coronary intervention is the preferred reperfusion strategy for acute ST-segment elevation myocardial infarction. During the opening of infarct-related vessels, 5%-50% of patients showed slow flow or no reflow and other coronary microcirculation dysfunction, which aggravated myocardial injury and increased the incidence and mortality of heart failure. Studies have shown that recombinant human brain natriuretic peptide (rhBNP) can reduce reperfusion injury and reduce myocardial infarction area CMD. Prolonged ischemia leads to rapid depletion of intracellular ATP and tissue metabolic acidosis. Blood flow irrigation during reperfusion leads to decreased levels of ATP precursors, calcium overload in mitochondria, release of a large number of inflammatory factors and oxygen free radicals, which can lead to injury or death of myocardial and endothelial cells. rhBNP can enhance the activity of antioxidant enzymes, reduce the irreversible oxidative damage caused by free radicals to myocardium, reduce the myocardial infarction area during ischemia reperfusion, and may reduce the reperfusion injury and protect the viable myocardium.
688 studies on the registry are indexed under ST Elevation Myocardial Infarction; 184 are open to participants now.
This study's planned enrollment of 160 is below the median of 194 across 439 interventional studies indexed under ST Elevation Myocardial Infarction.
Browse ST Elevation Myocardial Infarction studies →Henan Institute of Cardiovascular Epidemiology is the lead sponsor of 31 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The experimental group was given neoptin within 3h after PCI for 72 hours (first at 1.5μg /kg intravenous load, then at 0.015μg /kg/min).
Drug: recombinant human B-type natriuretic peptide
The experimental group was given an intravenous infusion of the same amount of normal saline
The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
Also known as: rhBNP
MVO/LV(%)
Microvascular obstruction assessed by magnetic resonance imaging
Time frame: 3-14 days after PPCI
LGE/LV(%)
Cardiac magnetic resonance imaging
Time frame: 3-14 days and 90±7 days after PPCI
IMH
Intramuscular hemorrhageCardiac assessed by magnetic resonance imaging
Time frame: 3-14 days after PPCI
MVO/LV(%)
Microvascular obstruction assessed by magnetic resonance imaging
Time frame: 30±7 days after PPCI
LVEDV(ml)
Assessed by magnetic resonance imaging
Time frame: 3-14 days and 90±7 days after PPCI
LVESV(ml)
Assessed by magnetic resonance imaging
Time frame: 3-14 days and 90±7 days after PPCI
Troponin (highest value)
Troponin (highest value)
Time frame: 3-14 days after PPCI
MACCEs
Major Adverse Cardiac and Cerebrovascular event：Death, nonfatal myocardial infarction, heart failure, revascularization, stroke
Time frame: 7days，30days，3months，6 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2023; primary completion for Dec 2024, 22 months later.
Of 119 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 74. This study's planned 22 months is below that.
Counting every sponsor, half of 125 studies reached it within 38 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Henan Institute of Cardiovascular Epidemiology